Skip to main content
. 2019 Jan 25;3(2):261–267. doi: 10.1002/rth2.12177

Table 4.

Relationships of AAV5 and AAV8 seroprevalence with plasma product use, human immunodeficiency virus status and hepatitis C (exposure and status) (% positive)

Plasma (% positive) HIV (% positive) Hepatitis C exposure (% positive) Hepatitis C status (% positive)
AAV5 TI 28 17 40* 36
AAV5 TAb 22 17 33* 41*
AAV8 TI 41 17 48 50
AAV8 TAb 27* 0 33* 36

*< 0.05.